TG Therapeutics (TGTX) Launches TGR-1202 Phase 12 in r/r Lymphoma
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- S&P, Dow open flat as Middle East jitters ease, Netflix weighs on Nasdaq
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Stocks off two-month low as fear of Middle East escalation eases
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- Netflix, Tesla, Amex, P&G fall premarket; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
TG Therapeutics, Inc. Announces the Launch of the Phase 1/2 Study of TGR-1202 and Carfilzomib in Patients with Relapsed or Refractory Lymphoma
October 20, 2016 8:50 AM EDTPhase 1/2 Study to be conducted at Columbia University Medical Center
First trial to combine these two treatments to explore the synergistic effects seen on c-Myc inhibition in extensive preclinical testing
NEW YORK, Oct. 20, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the launch of a Phase 1/2 study to evaluate the safety and efficacy of TGR-1202, the Company's oral PI3K delta inhibitor in combination with carfilzomib, the FDA-approved proteasome inhibitor, in patients with relapsed or refractory lymphoma. Â
The rationale for combining these two agents is based on... More
